Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 280
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT06861413 | A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation | ||
| NCT05535959 | A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor | ||
| NCT03625466 | A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del | ||
| NCT01614457 | Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT) | ||
| NCT01830985 | A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis | ||
| NCT05866055 | A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults | ||
| NCT00623649 | Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection | ||
| NCT00909727 | Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation | ||
| NCT03029455 | A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis | ||
| NCT01459913 | Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype | ||
| NCT04923464 | A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis | ||
| NCT03525444 | A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) | ||
| NCT02742519 | A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation | ||
| NCT05437120 | Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment | ||
| NCT06508762 | A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993 | ||
| NCT00621296 | Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C | ||
| NCT02445053 | Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study) | ||
| NCT01754935 | A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor | ||
| NCT00372385 | Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C | ||
| NCT04545515 | A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes | ||
| NCT03525548 | A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F) | ||
| NCT03912233 | A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis | ||
| NCT04786262 | A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes | ||
| NCT06345755 | A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants | ||
| NCT05865171 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment | ||
| NCT03795363 | Orkambi Treatment in 2 to 5 Year Old Children With CF | ||
| NCT06392659 | A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults | ||
| NCT00781274 | Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy | ||
| NCT06312787 | A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation | ||
| NCT01554085 | First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 | ||
| NCT03304522 | A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy | ||
| NCT04058366 | Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy | ||
| NCT01614470 | Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation | ||
| NCT06834009 | A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult Panelists | ||
| NCT03655678 | A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia | ||
| NCT05668741 | A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) | ||
| NCT06887972 | A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries | ||
| NCT01842451 | A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C | ||
| NCT01897233 | Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation | ||
| NCT06176196 | Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR) | ||
| NCT05791201 | A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes | ||
| NCT01117012 | Rollover Study of VX-770 in Cystic Fibrosis Subjects | ||
| NCT02392234 | A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation | ||
| NCT01888393 | Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects | ||
| NCT01890772 | Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1 | ||
| NCT05444257 | A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy | ||
| NCT07349394 | Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants | ||
| NCT01018368 | Study of VX-770 and Rifampin in Healthy Male Subjects | ||
| NCT06887959 | A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries | ||
| NCT04537793 | Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years |
